What is the ASCO Plenary Series?

The ASCO Plenary Series is a new educational program from ASCO featuring practice-changing and clinically relevant studies on the latest advances in cancer care. Each month, up to two abstracts will be presented in a live, one-hour online session. Each abstract presentation will be accompanied by a discussant presentation and followed by a live question and answer session. (Sessions will take place monthly through April and will resume after the ASCO Annual Meeting.)

Why did ASCO start this program?

ASCO recognizes that today’s science can’t wait. We developed the ASCO Plenary Series so researchers and clinicians can stay current on cutting-edge research in oncology in between meetings. The Plenary Series will provide faster dissemination of practice-changing science to better help clinicians deliver the most up-to-date care and treatments to patients.

How do I attend and access the Plenary Series presentations?

The ASCO Plenary Series is an exclusive benefit of ASCO Annual Meeting registration. If you registered for the 2021 Annual Meeting, you will automatically have access to the Series through April 2022. Registrants of the 2022 Annual Meeting will have access to all previous and upcoming monthly sessions through April 2023.

When do ASCO Plenary Series presentations take place? What if I am not able to attend the live presentation?

Presentations will happen on a monthly basis through April and resume after the ASCO Annual Meeting. For specific session dates and times, please visit the Program.

ASCO Annual Meeting registrants will have access to all Plenary Series content, including the live presentation as well as on-demand slides and videos following the presentation. If you are unable to join the live session, on-demand content will be available shortly thereafter.

What are the abstract eligibility criteria for submission?

Abstracts submitted to the ASCO Plenary Series should address novel scientific questions, detail clinical observations, and contain primary scientific data in the form of a randomized phase II and III trial OR be original research studies that highlight novel and high-impact research with practice-changing implications. Please refer to the eligibility criteria for more detailed information.

What is the abstract review and selection process?

All abstracts will be peer-reviewed by the ASCO Plenary Series Scientific Review Committee and evaluated on the following criteria:

  • Strength of Science: Does the research address an important and novel question?
  • Research Design: Are the eligibility criteria, study endpoints, and planned analysis well-defined in this abstract?
  • Relevance: Are the results practice-changing? Will they have a clinical impact and be of broad interest to the ASCO community?

Abstracts of superior quality will be selected for oral presentation and for publication in a supplement to the Journal of Clinical Oncology.

How will the ASCO Plenary Series abstracts be cited?

Abstracts will be published as an online supplement to the Journal of Clinical Oncology and carry JCO citations, for example, J Clin Oncol 39, 2021 (suppl 1, abstr 1).

When will abstracts for the ASCO Plenary Series be released by ASCO?

Abstracts will be publicly released at 5:00 p.m. ET on the day before presentation.

When does confidentiality/embargo lift on ASCO Plenary Series abstracts?

All abstracts submitted to the ASCO Plenary Series are subject to the Prior Presentation/Publication and Confidentiality Policies.

Confidentiality for all abstracts accepted for presentation in the ASCO Plenary Series will lift when the abstracts are publicly released by ASCO. The embargo will also lift concurrently at that time.

Are there advertising opportunities available?

Advertising opportunities are available. For more information, contact Alesha.Neely@asco.org.